Andere Kunden interessierten sich auch für
![Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account]( "Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account")
Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account54,99 €![The Challenge of CMC Regulatory Compliance for Biopharmaceuticals]( "The Challenge of CMC Regulatory Compliance for Biopharmaceuticals")
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals117,99 €![International Regulatory Approaches to Bioequivalence of Generic OIDPs]( "International Regulatory Approaches to Bioequivalence of Generic OIDPs")
International Regulatory Approaches to Bioequivalence of Generic OIDPs32,99 €![The Antimicrobial Resistance Regulatory Strategy]( "The Antimicrobial Resistance Regulatory Strategy")
The Antimicrobial Resistance Regulatory Strategy47,95 €![The Challenge of CMC Regulatory Compliance for Biopharmaceuticals]( "The Challenge of CMC Regulatory Compliance for Biopharmaceuticals")
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals158,99 €![Impact of Regulatory Environment on Pharmaceutical Industry]( "Impact of Regulatory Environment on Pharmaceutical Industry")
Impact of Regulatory Environment on Pharmaceutical Industry32,99 €![A Concise book on Pharmaceutical Regulatory Affairs]( "A Concise book on Pharmaceutical Regulatory Affairs")
A Concise book on Pharmaceutical Regulatory Affairs59,99 €
A biosimilar is a biological medicinal product which is a copy of an original (innovator) product. The innovator product is often manufactured by a different company and after the patent of the innovator product expires a biosimilar can be registered in the European Union to a lower price than the innovator product. The first biosimilar in the European Union was registered in 2006 and was a Somatropin compound. Now are about 20 biosimilars registered in the European Union. Forecasts expect that there will be a huge amount of biosimilars pushing on the market in the near future and that will have a big influence on the industry.